MetaCap

Lantheus (LNTH) vs Alpha Teknova (TKNO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Lantheus (LNTH) has outperformed Alpha Teknova (TKNO) over the past year, gaining 82.9% versus a gain of 77.4%. Over five years, LNTH leads with a +266.1% price change compared with -63.6% for TKNO. Lantheus is the larger company by market cap ($6.68 billion vs $480.0 million), about 13.9 times the size, while Alpha Teknova is growing revenue faster (+7.4% vs +0.5%).

Lantheus converts more of its revenue into profit, with a net margin of 15.2% versus -42.6%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

LNTH+82.91%TKNO+77.44%
+126%+32%-62%
Nov 21, 20251 yearNov 20, 2026
LNTH+255.87%TKNO-69.50%
+351%+117%-116%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

LNTH versus TKNO key metrics
MetricLNTHTKNO
Share price$102.10$7.63
Market cap$6.68B$479.95M
1-day change0.00%-2.30%
YTD return+53.42%+100.79%
1-year return+82.91%+77.44%
5-year return+266.08%-63.63%
P/E ratio (TTM)25.40—
Forward P/E15.34—
EPS (TTM)$4.02$-0.30
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$1.54B$40.52M
Revenue growth (YoY)+0.50%+7.35%
Net income (latest FY)$233.56M$-17.26M
Gross margin61.10%33.17%
Operating margin20.16%-41.90%
Net margin15.15%-42.59%
52-week high$111.86$9.48
52-week low$54.94$1.91
Distance from 52-week high-8.73%-19.51%
Analyst consensusholdnone
Avg. price target upside+3.81%+28.83%
Average volume1.02M437.31K
Shares outstanding65.40M62.90M
Employees1,193158
SectorHealth CareHealth Care
IndustryBiotechnology: In Vitro & In Vivo Diagnostic SubstancesBiotechnology: In Vitro & In Vivo Diagnostic Substances

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Lantheus is about 13.9 times larger than Alpha Teknova by market value ($6.68B vs $479.95M).
  • Lantheus is more profitable, keeping 15.2 cents of every revenue dollar as net income versus -42.6 cents for Alpha Teknova.
  • Alpha Teknova grew revenue faster in its latest fiscal year (+7.35% vs +0.50%).

About Lantheus

LNTH stock →

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide.

Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 1,193 employees

About Alpha Teknova

TKNO stock →

Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally.

Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 158 employees

LNTH vs TKNO FAQ

Which is bigger, Lantheus or Alpha Teknova?

Lantheus (LNTH) is larger, with a market capitalization of $6.68B compared with $479.95M for Alpha Teknova (TKNO).

Which stock has performed better over the past year, LNTH or TKNO?

LNTH returned +82.91% over the past 12 months, compared with +77.44% for TKNO (price return, excluding dividends). Past performance does not predict future results.

Are Lantheus and Alpha Teknova in the same industry?

Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.

More comparisons